GTx Stock Company Profile

Description

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other serious medical conditions. The company is developing selective androgen receptor modulators to treat a range of serious diseases, including breast cancer, stress urinary incontinence, and Duchenne muscular dystrophy; and selective androgen receptor degrader for the treatment of castration resistant prostate cancer. Its products include enobosarm, a Phase II open-label proof-of-concept clinical trial for patients with advanced AR positive TNBC and ER positive/AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.